Nusinersen in type 1 spinal muscular atrophy: Twelve‐month real‐world data-Reference-Cited by-同舟云学术

Nusinersen in type 1 spinal muscular atrophy: Twelve‐month real‐world data

Published:2019-07-08 Issue:3 Volume:86 Page:443-451
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol

Author:

Pane Marika¹,Coratti Giorgia¹,Sansone Valeria A.²,Messina Sonia³,Bruno Claudio⁴,Catteruccia Michela⁵,Sframeli Maria³,Albamonte Emilio²,Pedemonte Marina⁴,D'Amico Adele⁵,Bravetti Chiara¹,Berti Beatrice¹,Brigati Giorgia⁴,Tacchetti Paola⁴,Salmin Francesca²,de Sanctis Roberto¹,Lucibello Simona¹,Piastra Marco⁶,Genovese Orazio⁶,Bertini Enrico⁵,Vita Giuseppe³,Tiziano Francesco Danilo⁷,Mercuri Eugenio¹⁸^ORCID,

Affiliation:

1. Paediatric Neurology and Neuromuscular Omnicentre Clinical CenterAgostino Gemelli University Polyclinic Foundation, Scientific Institute for Research and Health Care Rome

2. Neurorehabilitation UnitUniversity of Milan, Neuromuscular Omnicentre Clinical Center, Niguarda Hospital Milan

3. Department of Clinical and Experimental MedicineUniversity of Messina and Neuromuscular Omnicentre Clinical Center Messina

4. Center of Myology and Neurodegenerative DisordersGiannina Gaslini Institute Genoa

5. Unit of Neuromuscular and Neurodegenerative DisordersBaby Jesus Children's Hospital Rome

6. Pediatric Intensive Care Unit, Catholic University and Gemelli General HospitalAgostino Gemelli University Polyclinic Foundation, Scientific Institute for Research and Health Care Rome

7. Institute of Genomic Medicine, Catholic University and Gemelli General HospitalAgostino Gemelli University Polyclinic Foundation, Scientific Institute for Research and Health Care Rome

8. Pediatric Neurology UnitCatholic University Rome Italy

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.25533

Reference24 articles.

1. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

2. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

3. Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience

4. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1

5. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment;Orphanet Journal of Rare Diseases;2024-09-13

2. Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy;Journal of Neurology;2024-09-06

3. Muscular MRI and magnetic resonance neurography in spinal muscular atrophy;CLIN RADIOL;2024

4. Muscular MRI and magnetic resonance neurography in spinal muscular atrophy;Clinical Radiology;2024-09

5. Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review;Muscle & Nerve;2024-08-11